Cited 36 times in
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이병완 | - |
dc.date.accessioned | 2020-12-01T17:24:44Z | - |
dc.date.available | 2020-12-01T17:24:44Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180257 | - |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kyung-Soo Kim | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.identifier.doi | 10.3350/cmh.2020.0137 | - |
dc.contributor.localId | A02796 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.identifier.pmid | 32791578 | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.citation.volume | 26 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 430 | - |
dc.citation.endPage | 443 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.26(4) : 430-443, 2020-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.